NCT04599452Unknown1 期
Safety and Efficacy of Allogeneic NK Cell Therapy for Recurrent/Refractory Elderly AML
适应症
干预措施
试验速览
- 阶段
- 1 期
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR) (PR+CR)
研究概览
简要总结
The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The 2 or more than 2-cycles of standard regimen was used to treat elderly AML patients who did not achieve complete remission or relapse.
- •Patients with age 60 years to 70 years.
- •KPS greater than or equal to
- •ALT and AST are less than 3 times normal.
- •Total bilirubin less than 1.5mg/dl(25.65umol/L).
- •Serum creatinine less than 2.5mg/dl(221umol/L), or creatinine scavenging ability greater than or equal to 60 mL/min/1.73 m
- •Left ventricular ejection fraction cardiac greater than or equal to 45%, Echocardiography (ECHO) showed no pericardial effusion, Electrocardiogram (ECG) is normal.
- •No pleural effusion in lungs
- •Oxyhemoglobin saturation greater than or equal to 92% in normal environment.
- •KIR mismatch between patient and umbilical cord blood.
- •Volunteer to participate in the trial and sign the informed consent form.
排除标准
- •Malignant tumor patient.
- •Patients who are accompanied by fungal, bacterial, viral, or other uncontrolled infections or require level 4 isolation( HBV-DNA quantification and normal liver function in patients with hepatitis b infection are excluded).
- •Patients with HIV, HCV positive.
- •Patients with central nervous system diseases, including stroke, epilepsy, dementia, or autoimmune central nervous system disorders.
- •During the first 12 months of enrollment, patients with cardioangiography or stents, active angina pectoris or other clinically significant symptoms, or with cardiogenic asthma.
- •Patients receiving anticoagulant therapy or with severe coagulation disorders.
- •According to the researcher's judgment, the drug treatment the patient is receiving will affect the safety and effectiveness of the study.
- •Patients with allergies or history of allergies to biological agents used in this program.
- •Systemic steroid used within 2 weeks before treatment (except for recent or present use of inhaled corticosteroids).
- •Patients with other uncontrolled diseases, Investigators think it is not suitable for the participants.
- •Any circumstance that the investigator considers may increase the risk to the subject or interfere with the results of the study.
- •Patients participate in other clinical studies.
研究组 & 干预措施
10 patients with recurrent refractory elderly AML were treated
Experimental
The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.
干预措施: Allogeneic NK cell regimen group (Biological)
结局指标
主要结局
Objective Response Rate (ORR) (PR+CR)
时间窗: 3 months
The proportion of patients with complete response(CR) or partial response(PR) as measured by response criteria definitions for acute myeloid leukemia
次要结局
- Overall survival(OS)(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Allogenic NK Cell Transfusion Azacitidine MDS-EBMDS-EBNCT04599426The Second Hospital of Shandong University10
Unknown
1 期
Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT04162158Beijing 302 Hospital200
尚未招募
早期 1 期
Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological MalignanciesHematological MalignanciesNCT04662788Zhejiang University36
Unknown
1 期
NK Cells Infusion for Advanced MalignanciesImmunotherapyNCT03619954Anhui Provincial Hospital50
Unknown
早期 1 期
Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR MutationNK Cell Mediated ImmunityNCT03662477Shenzhen Fifth People's Hospital10